MX386702B - Tratamiento con halogeno de ataque cardiaco y lesion isquemica. - Google Patents

Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Info

Publication number
MX386702B
MX386702B MX2016010328A MX2016010328A MX386702B MX 386702 B MX386702 B MX 386702B MX 2016010328 A MX2016010328 A MX 2016010328A MX 2016010328 A MX2016010328 A MX 2016010328A MX 386702 B MX386702 B MX 386702B
Authority
MX
Mexico
Prior art keywords
heart attack
ischemic injury
halogen treatment
compounds
halogen
Prior art date
Application number
MX2016010328A
Other languages
English (en)
Other versions
MX2016010328A (es
Inventor
Akiko Iwata
Michael L Morrison
Mark B Roth
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Publication of MX2016010328A publication Critical patent/MX2016010328A/es
Publication of MX386702B publication Critical patent/MX386702B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/16—Fluorine compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/18—Iodine; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A61K38/063—Glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)

Abstract

La presente invención se refiere al uso de compuestos de halógeno, incluyendo yoduro, y compuestos de calcogenuro, incluyendo yoduro, sulfuro y seleniuro, para tratar y prevenir enfermedades y lesiones; la presente invención se refiere además a composiciones que comprenden un compuesto de halógeno o un compuesto de calcogenuro, incluyendo composiciones farmacéuticas, así como métodos de fabricación de tales compuestos y la administración de tales composiciones a sujetos en necesidad de los mismos.
MX2016010328A 2014-02-10 2015-02-10 Tratamiento con halogeno de ataque cardiaco y lesion isquemica. MX386702B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937943P 2014-02-10 2014-02-10
US201462007015P 2014-06-03 2014-06-03
US201462060338P 2014-10-06 2014-10-06
US201462082957P 2014-11-21 2014-11-21
PCT/US2015/015227 WO2015120458A1 (en) 2014-02-10 2015-02-10 Halogen treatment of heart attack and ischemic injury

Publications (2)

Publication Number Publication Date
MX2016010328A MX2016010328A (es) 2017-02-06
MX386702B true MX386702B (es) 2025-03-19

Family

ID=53778544

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016010328A MX386702B (es) 2014-02-10 2015-02-10 Tratamiento con halogeno de ataque cardiaco y lesion isquemica.

Country Status (16)

Country Link
US (4) US10201570B2 (es)
EP (1) EP3104939B1 (es)
JP (2) JP6573620B2 (es)
KR (1) KR102304113B1 (es)
CN (1) CN106102836B (es)
AU (1) AU2015213577B2 (es)
CA (1) CA2937800C (es)
ES (1) ES2987484T3 (es)
IL (1) IL246431B (es)
MX (1) MX386702B (es)
NZ (1) NZ721500A (es)
PL (1) PL3104939T3 (es)
PT (1) PT3104939T (es)
RU (1) RU2728790C2 (es)
WO (1) WO2015120458A1 (es)
ZA (1) ZA201604785B (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304113B1 (ko) 2014-02-10 2021-09-24 프레드 헛친슨 켄서 리서치 센터 심장마비 및 허혈성 손상의 할로겐 치료
FI3200582T3 (fi) 2014-09-29 2024-02-14 Fred Hutchinson Cancer Center Koostumuksia, tarvikesarjoja ja menetelmiä hankinnaisen sytoresistanssin indusointiin stressiproteiinin indusoijia käyttämällä
WO2017173308A1 (en) 2016-03-31 2017-10-05 Goergetown University Radiation mitigator and method of use thereof
EP3496696A4 (en) * 2016-08-11 2020-04-22 Sulfilatec, Inc. COMPOUNDS AND METHODS FOR TREATING THE DISEASE.
US20190358242A1 (en) * 2017-02-08 2019-11-28 Fred Hutchinson Cancer Research Center Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
JP7237366B2 (ja) 2017-12-29 2023-03-13 国立大学法人大阪大学 アスタチン溶液及びその製造方法
US20210252047A1 (en) * 2018-06-08 2021-08-19 Faraday Pharmaceuticals, Inc. Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome
US12313635B2 (en) 2018-07-27 2025-05-27 The Regents Of The University Of California Biomarker for thoracic aortic aneurysm
RU2712448C1 (ru) * 2019-05-14 2020-01-29 Федеральное Государственное Бюджетное Научное Учреждение "Федеральный Научно-Клинический Центр Реаниматологии и Реабилиталогии" (ФНКЦ РР) Способ кардиопротекции ишемических и реперфузионных повреждений в остром периоде инфаркта миокарда
CN110331162B (zh) * 2019-06-12 2021-02-19 温州医科大学 一种主动脉夹层特异性诱导多能干细胞及疾病模型应用
CN114929246A (zh) * 2019-11-04 2022-08-19 法拉第制药公司 碘化物化合物用于治疗和预防化学疗法相关的恶病质和心脏毒性的用途
CN112136765B (zh) * 2020-09-29 2022-03-29 河南省农业科学院畜牧兽医研究所 一种猪卵巢氧化应激模型及其构建方法和用途

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364555A (en) 1991-04-30 1994-11-15 Advanced Oxygen Technologies, Inc. Polymer compositions containing salicylic acid chelates as oxygen scavengers
US6458758B1 (en) 1993-08-16 2002-10-01 Synzyme Technologies, Inc. Compositions and methods utilizing nitroxides in combination with biocompatible macromolecules
US6316208B1 (en) 1994-01-07 2001-11-13 Memorial Sloan-Kettering Cancer Center Methods for determining isolated p27 protein levels and uses thereof
US5688665A (en) 1994-01-07 1997-11-18 Fred Hutchinson Cancer Research Center Isolated nucleic acid molecules encoding the p27 KIP-1 protein
AU2770695A (en) 1994-07-15 1996-02-16 Fred Hutchinson Cancer Research Center Isolated p27 protein and methods for its production and use
EP0877796A4 (en) 1996-01-18 2002-01-02 Hutchinson Fred Cancer Res COMPOSITIONS AND METHODS FOR MEDIATING THE PROGRESS OF THE CELL CYCLE
US6350467B1 (en) 1996-12-31 2002-02-26 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
US6248335B1 (en) 1997-10-29 2001-06-19 Symbollon Corporation Stabilized oral pharmaceutical composition containing iodide and iodate and method
US5885592A (en) * 1997-10-29 1999-03-23 Symbollon Corporation Methods and pharmaceutical compositions for oral delivery of molecular iodine
GB0022922D0 (en) * 2000-09-19 2000-11-01 Chapman Robert E Compounds for use in medicine
US6534676B2 (en) * 2001-01-31 2003-03-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same
US6716877B2 (en) * 2001-01-31 2004-04-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Method to treat chronic heart failure and/or elevated cholesterol levels
US20050053912A1 (en) 2001-06-11 2005-03-10 Roth Mark B. Methods for inducing reversible stasis
CA2453478A1 (en) * 2001-07-18 2003-01-30 Ono Pharmaceutical Co., Ltd. Agent for treatment of cerebral ischemic diseases
US7169377B2 (en) * 2003-10-15 2007-01-30 Wei Edward T Radioligands for the TRP-M8 receptor and methods therewith
AU2004285468B2 (en) 2003-10-22 2011-02-24 Fred Hutchinson Cancer Research Center Methods, compositions and devices for inducing stasis in cells, tissues, organs, and organisms
US20050106214A1 (en) 2003-11-14 2005-05-19 Guohua Chen Excipients in drug delivery vehicles
US20100048513A1 (en) 2008-08-20 2010-02-25 Hawkins Michael J Novel inhibitors of chymase
CA2605631A1 (en) 2005-04-20 2006-10-26 Fred Hutchinson Cancer Research Center Methods, compositions and articles of manufacture for enhancing survivability of cells, tissues, organs, and organisms
JP2008542301A (ja) 2005-05-26 2008-11-27 メタバシス・セラピューティクス・インコーポレイテッド 脂肪性肝疾患の処置のための甲状腺ホルモン様薬剤
GB0525504D0 (en) 2005-12-14 2006-01-25 Bristol Myers Squibb Co Antimicrobial composition
US20070265223A1 (en) 2006-03-10 2007-11-15 Ikaria, Inc. Compositions and methods of enhancing survivability and reducing injury of cells, tissues, organs, and organisms under hypoxic or ischemic conditions
CA2646674A1 (en) 2006-04-20 2007-11-01 Fred Hutchinson Cancer Research Center Use of chalcogenides for treating shock and other adverse conditions
US7589076B2 (en) 2006-05-18 2009-09-15 Pgx Health, Llc Substituted aryl piperidinylalkynyladenosines as A2AR agonists
WO2008005980A1 (en) * 2006-07-03 2008-01-10 Hill's Pet Nutrition, Inc. Copositions and methods for preventing or treating cardiovascular diseases in felines with hyperthyroidism
US20090011051A1 (en) 2006-09-28 2009-01-08 Roth Mark B Methods, Compositions and Articles of Manufacture for HIF Modulating Compounds
KR101538727B1 (ko) 2006-10-05 2015-07-22 이카리아 인코포레이티드 액체 칼코게나이드 조성물 및 이의 제조방법과 사용방법
US20100143503A1 (en) 2006-12-22 2010-06-10 Ikaria, Inc. Combinations of nitric oxide and sulfide and methods of use and manufacture thereof
US20120135091A1 (en) 2007-01-18 2012-05-31 Roth Mark B Methods and compositions for enhancing lifespan involving sirtuin-modulating compounds and chalcogenides
US7858379B2 (en) 2007-06-05 2010-12-28 Lynntech, Inc. Apparatus and method for determining the concentration of iodine-containing organic compounds in an aqueous solution
WO2008157393A1 (en) 2007-06-15 2008-12-24 Ikaria, Inc. Compositions comprising sulfide alone or in combination with nitric oxide and their use to
WO2009003061A1 (en) 2007-06-25 2008-12-31 Fred Hutchinson Cancer Research Center Methods and compositions regarding polychalcogenide compositions
JP2011503111A (ja) 2007-11-12 2011-01-27 バイパー サイエンシズ，インコーポレイティド Ｐａｒｐ阻害剤単独又は抗腫瘍剤との組み合わせによる乳がんの治療
PL2245056T4 (pl) 2008-01-22 2016-01-29 Araim Pharmaceuticals Inc Peptydy i analogi peptydowe chroniące tkanki do zapobiegania i leczenia chorób i schorzeń związanych z uszkodzeniem tkanek
US7745150B2 (en) * 2008-03-07 2010-06-29 The University Of Connecticut Methods for the detection and monitoring of congestive heart failure
EP2349236A2 (en) 2008-10-16 2011-08-03 Ikaria, Inc. Compositions and methods for treating or preventing hypoxic or ischemic injury
US20100183748A1 (en) 2009-01-21 2010-07-22 Ikaria, Inc. Methods for Treating or Preventing Radiocontrast Agent Induced Kidney Injury
US8680151B2 (en) 2010-02-11 2014-03-25 Fred Hutchinson Cancer Research Center Compounds, compositions and methods for treating or preventing hypoxic or ischemic injury
ES2791708T3 (es) 2010-04-28 2020-11-05 Ashur Fabian Osnat Composiciones que comprenden triyodotironina y un agente antitiroideo para el tratamiento del cáncer
WO2013003429A1 (en) 2011-06-28 2013-01-03 Ikaria, Inc. End-tidal gas monitoring apparatus
WO2013138520A1 (en) 2012-03-13 2013-09-19 University Of Tennessee Research Foundation Composition and system for transdermal delivery
US9566301B2 (en) * 2012-03-29 2017-02-14 Cxl Ophthalmics, Llc Compositions and methods for treating or preventing diseases associated with oxidative stress
JP2015527975A (ja) * 2012-06-13 2015-09-24 フレッド ハッチンソン キャンサー リサーチ センター カルコゲニドを含む組成物および関連方法
KR102304113B1 (ko) * 2014-02-10 2021-09-24 프레드 헛친슨 켄서 리서치 센터 심장마비 및 허혈성 손상의 할로겐 치료
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN106093215B (zh) 2016-05-26 2019-09-06 深圳合核环境科技有限公司 一种测量水中溶解性有机卤含量的方法及系统
US20200096496A1 (en) 2017-06-14 2020-03-26 Faraday Pharmaceuticals, Inc. Iodide detection in blood plasma samples
US20210252047A1 (en) 2018-06-08 2021-08-19 Faraday Pharmaceuticals, Inc. Use of halogen compounds for the treatment and prevention of tissue injury and post-intensive care syndrome
CN114929246A (zh) 2019-11-04 2022-08-19 法拉第制药公司 碘化物化合物用于治疗和预防化学疗法相关的恶病质和心脏毒性的用途
WO2021257806A1 (en) 2020-06-18 2021-12-23 Fred Hutchinson Cancer Research Center Iodide for treatment of nonthyroidal illness syndrome

Also Published As

Publication number Publication date
CN106102836A (zh) 2016-11-09
EP3104939B1 (en) 2024-05-01
JP2019194265A (ja) 2019-11-07
JP6573620B2 (ja) 2019-09-11
NZ721500A (en) 2022-11-25
RU2728790C2 (ru) 2020-07-31
US12016880B2 (en) 2024-06-25
US20220313730A1 (en) 2022-10-06
MX2016010328A (es) 2017-02-06
EP3104939A4 (en) 2017-10-04
IL246431B (en) 2021-05-31
PT3104939T (pt) 2024-07-17
AU2015213577A2 (en) 2016-08-04
CA2937800C (en) 2024-04-16
US10201570B2 (en) 2019-02-12
KR102304113B1 (ko) 2021-09-24
WO2015120458A1 (en) 2015-08-13
IL246431A0 (en) 2016-08-31
RU2016136411A3 (es) 2018-09-26
AU2015213577A1 (en) 2016-07-07
AU2015213577B2 (en) 2019-02-14
JP2017507929A (ja) 2017-03-23
US20250367232A1 (en) 2025-12-04
RU2016136411A (ru) 2018-03-15
ZA201604785B (en) 2020-01-29
US20160346323A1 (en) 2016-12-01
ES2987484T3 (es) 2024-11-15
EP3104939A1 (en) 2016-12-21
US20200016194A1 (en) 2020-01-16
PL3104939T3 (pl) 2024-09-30
CA2937800A1 (en) 2015-08-13
CN106102836B (zh) 2020-02-04
KR20160113624A (ko) 2016-09-30

Similar Documents

Publication Publication Date Title
MX386702B (es) Tratamiento con halogeno de ataque cardiaco y lesion isquemica.
CL2018002814A1 (es) Composiciones y metodos para el tratamiento de heridas, trastornos, y enfermedades de la piel.
LT3672954T (lt) Junginiai, jų druskos ir jų naudojimas ligoms gydyti
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
IL255509B (en) Compounds as modulators of ccr2, pharmaceutical preparations containing them and their use in the treatment of diseases
EA201790273A1 (ru) Флагеллиновые композиции и их применение
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EP3263132C0 (en) COMPOSITION FOR THE TREATMENT OF DISEASES ASSOCIATED WITH IL-6
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
WO2015171610A3 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
SI3346995T1 (sl) Terapevtski sestavek za zdravljenje virusa človeške imunske pomanjkljivosti
EP3171933C0 (en) PRECISION CHEMICAL ABLATION AND TISSUE TREATMENT
MX2017009417A (es) Formas solidas de acido 2-(5-(3-fluorofenil)-3-hidroxipicolinamido )acetico, composiciones y usos de las mismas.
EA201890449A1 (ru) Фумагиллиновые гетероциклические соединения и способы их получения и применения
MX2019001634A (es) Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos.
IL269083A (en) Methods for preventing and treating heart disease
EA201692111A1 (ru) Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
EA201691567A1 (ru) Способы лечения легких травм головного мозга
MX2018008640A (es) Derivados de 3-(carboxietil)-8-amino-2-oxo-1,3-diaza-espiro-[4.5]- decano.
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX380290B (es) Composiciones y métodos para el tratamiento y la prevención de trastornos neurodegenerativos.
EP3566702A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES SUCH AS ASTHMA OR ATOPIA, CONSISTING OF BAICALEIN AS THE ACTIVE SUBSTANCE
WO2016029136A8 (en) 3-amidobenzamides and uses thereof for increasing cellular levels of a3g
UA118474C2 (uk) (s)-пірліндол та його фармацевтично прийнятні солі для застосування в медицині
LT3124048T (lt) Kompozicija skirta vartoti per burną gastroezofaginio refliukso ligos ar skausmo gydymui